Malagón-Valdez J
Clinica para la Atención del Neurodesarrollado, Aguascalientes, Mexico.
Rev Neurol. 2004;39(6):570-5.
Although the significant progress in pharmacotherapy of epilepsy during last decade was achieved, about one third of patients are resistant to the current treatment. The introduction of numerous effective, well tolerated and safe new antiepileptic drugs (AEDs) in the last decade of the 20th century has widened the choice of treatment options in epilepsy and improved the tolerability and the ease of use of treating patients with epilepsy. Nevertheless, significant safety and efficacy deficits continue to exist. Severe idiosyncratic reactions and organ toxicity have hampered the wide use of some of the newer AEDs. As a decade before, about one third of patients with chronic epilepsy is resistant to current pharmacotherapy. Even in patients in whom pharmacotherapy is efficacious, current AEDs do not seem to affect the progression or the underlying natural history of epilepsy.
The revision of newer AEDs are formulation, action, doses and side effects.
Thus, there is an unmet need for safer and more effective drugs, especially for chronic, drug-resistant epilepsy. To stimulate the development of even better compounds, the demonstrated benefits and risks of current new AEDs are reviewed.
尽管在过去十年中癫痫药物治疗取得了显著进展，但仍有大约三分之一的患者对当前治疗耐药。20世纪最后十年引入了众多有效、耐受性良好且安全的新型抗癫痫药物（AEDs），这拓宽了癫痫治疗方案的选择范围，提高了癫痫患者治疗的耐受性和易用性。然而，显著的安全性和有效性缺陷依然存在。严重的特异反应和器官毒性阻碍了一些新型AEDs的广泛应用。与十年前一样，约三分之一的慢性癫痫患者对当前药物治疗耐药。即使在药物治疗有效的患者中，当前的AEDs似乎也不会影响癫痫的进展或潜在自然病程。
新型AEDs的修订内容包括剂型、作用机制、剂量和副作用。
因此，对更安全、更有效的药物存在未满足的需求，尤其是针对慢性耐药性癫痫。为推动研发更优的化合物，对当前新型AEDs已证实的益处和风险进行了综述。
